DE602006013406D1 - Meningokokken-konjugat-impfung - Google Patents

Meningokokken-konjugat-impfung

Info

Publication number
DE602006013406D1
DE602006013406D1 DE602006013406T DE602006013406T DE602006013406D1 DE 602006013406 D1 DE602006013406 D1 DE 602006013406D1 DE 602006013406 T DE602006013406 T DE 602006013406T DE 602006013406 T DE602006013406 T DE 602006013406T DE 602006013406 D1 DE602006013406 D1 DE 602006013406D1
Authority
DE
Germany
Prior art keywords
carrier protein
patient
tetanus toxoid
meningococcal
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006013406T
Other languages
English (en)
Inventor
Cameron John Marshall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis Vaccines and Diagnostics SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34224621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602006013406(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines and Diagnostics SRL filed Critical Novartis Vaccines and Diagnostics SRL
Publication of DE602006013406D1 publication Critical patent/DE602006013406D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE602006013406T 2005-01-14 2006-01-13 Meningokokken-konjugat-impfung Active DE602006013406D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0500787.7A GB0500787D0 (en) 2005-01-14 2005-01-14 Integration of meningococcal conjugate vaccination
PCT/GB2006/000120 WO2006075170A1 (en) 2005-01-14 2006-01-13 Meningococcal conjugate vaccination

Publications (1)

Publication Number Publication Date
DE602006013406D1 true DE602006013406D1 (de) 2010-05-20

Family

ID=34224621

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006013406T Active DE602006013406D1 (de) 2005-01-14 2006-01-13 Meningokokken-konjugat-impfung

Country Status (20)

Country Link
US (1) US8529908B2 (de)
EP (2) EP2193810A1 (de)
JP (3) JP5687405B2 (de)
CN (2) CN105126097A (de)
AT (1) ATE463261T1 (de)
AU (1) AU2006205656B2 (de)
BR (1) BRPI0606523A2 (de)
CA (1) CA2595128C (de)
CY (1) CY1110140T1 (de)
DE (1) DE602006013406D1 (de)
DK (1) DK1835939T3 (de)
ES (1) ES2343855T3 (de)
GB (1) GB0500787D0 (de)
MX (1) MX2007008537A (de)
NZ (1) NZ560201A (de)
PL (1) PL1835939T3 (de)
PT (1) PT1835939E (de)
RU (1) RU2429011C2 (de)
SI (1) SI1835939T1 (de)
WO (1) WO2006075170A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK288007B6 (sk) * 2000-06-29 2012-10-02 Glaxosmithkline Biologicals S. A. Multivalent vaccine composition, process for its producing, and its use
MXPA03006561A (es) 2001-01-23 2004-10-15 Aventis Pasteur Vacuna del conjugado proteina-polisacarido meningococico, multivalente.
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP2272531A3 (de) 2004-04-30 2011-04-13 Novartis Vaccines and Diagnostics S.r.l. Integration von Meningokokkenkonjugatimpfstoff
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US9931397B2 (en) 2005-06-27 2018-04-03 Glaxosmithkline Biologicals S.A. Immunogenic composition
CA2633789A1 (en) * 2005-12-23 2007-06-28 Glaxosmithkline Biologicals Sa Conjugate vaccines
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
RU2009149359A (ru) * 2007-06-04 2011-07-20 Новартис АГ (CH) Состав вакцин против менингита
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
HRP20210242T4 (hr) 2010-08-23 2024-05-10 Wyeth Llc Stabilne formulacije antigena iz bakterije neisseria meningitidis rlp2086
CN103096920B (zh) 2010-09-10 2016-03-23 惠氏有限责任公司 脑膜炎奈瑟球菌orf2086抗原的非脂质化变体
CN105693865B (zh) 2011-06-01 2020-07-17 厦门大学 包含白喉毒素无毒突变体crm197或其片段的融合蛋白
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
BR122016004924A2 (pt) 2012-03-09 2019-07-30 Pfizer Inc. Polipeptídeo isolado e composições imunogênicas compreendendo os mesmos
WO2014095771A1 (en) * 2012-12-18 2014-06-26 Novartis Ag Conjugates for protecting against diphtheria and/or tetanus
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
MX2019002489A (es) 2016-09-02 2019-10-21 Sanofi Pasteur Inc Vacuna contra neisseria meningitidis.
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP2020525495A (ja) * 2017-06-27 2020-08-27 エムエスディー ウェルカム トラスト ヒルマン ラボラトリーズ プライベート リミテッドＭｓｄ Ｗｅｌｌｃｏｍｅ Ｔｒｕｓｔ Ｈｉｌｌｅｍａｎ Ｌａｂｏｒａｔｏｒｉｅｓ Ｐｖｔ．Ｌｔｄ． 新規の多価多糖類・タンパク質のコンジュゲートワクチン組成物及びその製剤
US20200353064A1 (en) * 2018-01-29 2020-11-12 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel meningococcal vaccine composition and process thereof
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB323103A (en) 1928-12-07 1929-12-24 Fred Cunningham Firth Improvements relating to shaper mechanism for winding yarn on weft bobbins in spinning mules
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ241926A (en) 1988-08-25 1993-08-26 Liposome Co Inc Immunisation dosage form comprising a salt of an organic acid derivative of a sterol and an antigen
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US4965388A (en) 1990-01-02 1990-10-23 Dow Corning Corporation Method for preparing organohalosilanes
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
JP3755890B2 (ja) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
DK0658118T3 (da) 1992-08-31 2002-05-06 Baxter Healthcare Sa Vaccine mod Neisseria meningitidis, gruppe C
EP0812593B8 (de) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. 3-0-Deazylierte Monophosphoryl Lipid A enthaltende Impfstoff-Zusammensetzungen
ATE254475T1 (de) 1993-09-22 2003-12-15 Jackson H M Found Military Med Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
FR2734484B1 (fr) 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
JP4233113B2 (ja) 1995-06-07 2009-03-04 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム 多糖類抗原−キャリア蛋白接合体および遊離キャリア蛋白を有してなるワクチン
PL184872B1 (pl) 1995-06-23 2003-01-31 Smithkline Beecham Biolog Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
EP1005368B1 (de) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
JP4426091B2 (ja) 1997-09-05 2010-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニンを含有する水中油型エマルション
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
KR100585408B1 (ko) 1998-02-12 2006-06-01 와이어쓰 홀딩스 코포레이션 인터루킨-12로 제형된 폐렴구균 및 수막구균 백신
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
KR20010042573A (ko) 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
JP2004505885A (ja) 1998-08-19 2004-02-26 ノース　アメリカン　ワクチン，　インコーポレイテッド Ｎ−アクリロイル化ポリサッカリドを用いて産生されたワクチンとして有用な免疫原性β−プロピオンアミド連結ポリサッカリド−タンパク質結合体
AU750587B2 (en) 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
JP4846906B2 (ja) 1999-03-19 2011-12-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
WO2001021152A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
CA2396871A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
SK288007B6 (sk) 2000-06-29 2012-10-02 Glaxosmithkline Biologicals S. A. Multivalent vaccine composition, process for its producing, and its use
WO2002026757A2 (en) 2000-09-26 2002-04-04 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
MXPA03006561A (es) 2001-01-23 2004-10-15 Aventis Pasteur Vacuna del conjugado proteina-polisacarido meningococico, multivalente.
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
RU2323002C2 (ru) 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
US20030091593A1 (en) 2001-09-14 2003-05-15 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
DK1777236T3 (en) 2002-03-26 2017-02-27 Glaxosmithkline Biologicals Sa MODIFIED SUCCARIDES WHICH IMPROVED WATER STABILITY FOR USE AS A MEDICINE
EP1506007B1 (de) 2002-05-14 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Kombinationsimpfstoff gegen bakterielle meningitis, der über die schleimhaut appliziert wird
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
US20040096461A1 (en) 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
GB0217909D0 (en) 2002-08-01 2002-09-11 Du Pont Chintzed stretch fabrics
JP4697706B2 (ja) 2002-10-11 2011-06-08 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 高毒性髄膜炎菌系統に対する広範な防御のためのポリペプチド−ワクチン
CA2511646A1 (en) 2002-12-27 2004-07-22 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
EP1594524B1 (de) 2003-01-21 2012-08-15 Novartis Vaccines and Diagnostics, Inc. Verwendung von tryptanthrin-verbindungen zur immunverstärkung
EP2191844B1 (de) 2003-01-30 2014-03-05 Novartis AG Injizierbarer Impfstoff gegen multiple Meningokokken-Serogruppen
JP2007516219A (ja) 2003-05-07 2007-06-21 アヴェンティス パストゥール インコーポレイテッド 髄膜炎菌ワクチン接種に対する免疫原性の増強の方法
EP2386313A1 (de) 2003-05-07 2011-11-16 Sanofi Pasteur, Inc. Mehrwertige derivatisierte meningokokkale Polysaccharidproteinkonjugate und Vakzine
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
CA2530434A1 (en) 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Immunization method against neisseria meningitidis serogroups a and c
CN103623405B (zh) 2003-08-06 2016-06-15 美国政府健康及人类服务部 多糖-蛋白轭合物疫苗
EP2272531A3 (de) * 2004-04-30 2011-04-13 Novartis Vaccines and Diagnostics S.r.l. Integration von Meningokokkenkonjugatimpfstoff
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
CA2633789A1 (en) 2005-12-23 2007-06-28 Glaxosmithkline Biologicals Sa Conjugate vaccines

Also Published As

Publication number Publication date
SI1835939T1 (sl) 2010-08-31
RU2429011C2 (ru) 2011-09-20
US8529908B2 (en) 2013-09-10
DK1835939T3 (da) 2010-05-31
PT1835939E (pt) 2010-07-13
JP2012162580A (ja) 2012-08-30
AU2006205656B2 (en) 2012-04-19
BRPI0606523A2 (pt) 2009-06-30
JP2014144984A (ja) 2014-08-14
EP1835939B1 (de) 2010-04-07
CN101163508A (zh) 2008-04-16
CN105126097A (zh) 2015-12-09
JP5687405B2 (ja) 2015-03-18
AU2006205656A1 (en) 2006-07-20
EP2193810A1 (de) 2010-06-09
JP2008526939A (ja) 2008-07-24
MX2007008537A (es) 2007-08-14
CA2595128A1 (en) 2006-07-20
ATE463261T1 (de) 2010-04-15
RU2007130774A (ru) 2009-02-20
EP1835939A1 (de) 2007-09-26
CA2595128C (en) 2016-06-21
US20100104593A1 (en) 2010-04-29
ES2343855T3 (es) 2010-08-11
WO2006075170A1 (en) 2006-07-20
CY1110140T1 (el) 2015-01-14
GB0500787D0 (en) 2005-02-23
NZ560201A (en) 2009-11-27
PL1835939T3 (pl) 2011-06-30

Similar Documents

Publication Publication Date Title
DK1835939T3 (da) Meningokokkonjugatvaccination
ATE512670T1 (de) Meningokokken-konjugat-impfung
NZ598367A (en) Multiple vaccination including serogroup C meningococcus
EA200801344A1 (ru) Пневмококковая полисахаридная конъюгатная вакцина
BRPI0508813B8 (pt) vacinas líquidas de combinação com baixa dose de conjugado de hib
NO20015073D0 (no) Vaksiner
DK2004225T3 (da) Programmer for vaccination med meningocockonjugater
MA25824A1 (fr) Compostion de vaccin polyvalente
RU2006114677A (ru) Жидкие вакцины для множественных серогрупп менингококков
PE11298A1 (es) Vacunas
CR10123A (es) Vacuna.
DK2200642T3 (da) Meningococvaccinepræparater
MX2015013401A (es) Procedimiento de tratamiento.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS AG, BASEL, CH

8363 Opposition against the patent
R065 Request for grant of supplementary protection certificate validly filed

Free format text: PRODUCT NAME: KOMBINATION AUS EINEM NEISSERIA MENINGITIDIS-GRUPPE C-POLYSACCHARID, DAS AN EIN TETANUS-TOXOID-TRAEGERPROTEIN KONJUGIERT IST, UND EINEM NEISSERIA MENINGITIDIS-GRUPPE Y-POLYSACCHARID, DAS AN EIN TETANUS-TOXOID-TRAEGERPROTEIN KONJUGIERT IST; REGISTRATION NO/DATE: EU/1/12/767/001-007 20120420

Spc suppl protection certif: 122012000079

Filing date: 20121019

Expiry date: 20260114

Effective date: 20121108